Piflufolastat f18
Pylarify (piflufolastat f18) is a small molecule pharmaceutical. Piflufolastat f18 was first approved as Pylarify on 2021-05-26.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| pylarify | New Drug Application | 2024-06-17 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
PIFLUFOLASTAT F-18, PYLARIFY, PROGENICS PHARMS INC | |||
| 2026-05-26 | NCE | ||
HCPCS
Code | Description |
|---|---|
| A9595 | Piflufolastat f-18, diagnostic, 1 millicurie |
Clinical
Clinical Trials
82 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Prostatic neoplasms | D011471 | — | C61 | 14 | 24 | 10 | 6 | 22 | 70 |
| Adenocarcinoma | D000230 | — | — | — | 3 | 2 | 1 | 4 | 9 |
| Recurrence | D012008 | — | — | — | — | 2 | 1 | 3 | 6 |
| Neoplasms | D009369 | — | C80 | 1 | 3 | — | 1 | — | 5 |
| Castration-resistant prostatic neoplasms | D064129 | — | — | — | 1 | — | 3 | — | 4 |
| Urogenital neoplasms | D014565 | EFO_0003863 | D07 | — | 1 | — | 1 | — | 2 |
| Neoplasms by site | D009371 | — | — | — | 1 | — | 1 | — | 2 |
| Male genital diseases | D005832 | EFO_0009555 | N50.9 | — | 1 | — | 1 | — | 2 |
| Prostatic diseases | D011469 | — | N42.9 | — | 1 | — | 1 | — | 2 |
| Male genital neoplasms | D005834 | — | — | — | 1 | — | 1 | — | 2 |
Show 5 more
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Carcinoma | D002277 | — | C80.0 | 2 | 3 | — | — | 2 | 6 |
| Renal cell carcinoma | D002292 | EFO_0000376 | — | 1 | 2 | — | — | 2 | 4 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | 1 | 2 | — | — | 1 | 4 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 1 | 2 | — | — | — | 3 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 1 | — | — | — | 2 |
| Triple negative breast neoplasms | D064726 | — | — | — | 1 | — | — | — | 1 |
| Female genital neoplasms | D005833 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neurilemmoma | D009442 | EFO_0000693 | — | 1 | — | — | — | — | 1 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neuroblastoma | D009447 | EFO_0000621 | — | — | — | — | — | 1 | 1 |
| Neuroendocrine tumors | D018358 | EFO_1001901 | D3A.8 | — | — | — | — | 1 | 1 |
| Paraganglioma | D010235 | — | — | — | — | — | — | 1 | 1 |
| Carcinoid tumor | D002276 | — | D3A.00 | — | — | — | — | 1 | 1 |
| Glioma | D005910 | EFO_0000520 | — | — | — | — | — | 1 | 1 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | — | — | — | — | 1 | 1 |
| Ovarian epithelial carcinoma | D000077216 | — | — | — | — | — | — | 1 | 1 |
| Disease progression | D018450 | — | — | — | — | — | — | 1 | 1 |
| Prostatectomy | D011468 | — | — | — | — | — | — | 1 | 1 |
| Kidney neoplasms | D007680 | EFO_0003865 | C64 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Piflufolastat f18 |
| INN | piflufolastat (18f) |
| Description | Piflufolastat F-18, sold under the brand name Pylarify among others, is a radioactive diagnostic agent used for positron emission tomography (PET) imaging. It is given by intravenous injection.
|
| Classification | Small molecule |
| Drug class | enzyme inhibitors: folate hydrolose (also called Prostate Specific Membrane Antigen (PSMA) or glutamate carboxypeptidase II) inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | O=C(O)CC[C@H](NC(=O)N[C@@H](CCCCNC(=O)c1ccc([18F])nc1)C(=O)O)C(=O)O |
Identifiers
| PDB | — |
| CAS-ID | 1207181-29-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4297334 |
| ChEBI ID | — |
| PubChem CID | 52950901 |
| DrugBank | DB14805 |
| UNII ID | 3934EF02T7 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
115 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use